Abstract
The aim of this work was to preliminarily evaluate the sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of 68Ga-citrate PET/CT in a population of patients with suspected bone infections. Methods: We enrolled 31 patients with suspected osteomyelitis or diskitis who underwent a total of forty 68Ga-citrate PET/CT scans. The results were compared with different combinations of diagnostic procedures (MRI, radiography, CT, or white blood cell scintigraphy), biopsy (when diagnostic), and follow-up data (at least 1 y) to determine the performance of 68Ga-citrate PET/CT. Results: We found a sensitivity of 100%, a specificity of 76%, a positive predictive value of 85%, a negative predictive value of 100%, and an overall accuracy of 90%. Conclusion: Although preliminary, these data confirm a possible role for 68Ga-citrate in the diagnosis of bone infections, especially in consideration of its favorable characteristics.
Gallium is a metallic ion that is taken up by infectious and inflammatory sites (1). However, 67Ga-citrate scintigraphy shows some disadvantages. The limited injectable activity (due to the long half-life) and the wide spectrum of gammas emitted by 67Ga reduce image quality and resolution. The images are low-resolution, sometimes completed by a SPECT acquisition. 67Ga is an expensive isotope and must be purchased commercially. Finally, the entire diagnostic procedure is long, lasting 3 d.
A germanium/gallium generator producing 68Ga has recently become commercially available (2). 68Ga is a positron-emitting gallium isotope that can be used for PET diagnostics.
Theoretically, the use of this isotope of gallium in the form of 68Ga-citrate presents many advantages over 67Ga for the diagnosis of bone infections. Its half-life is much shorter than that of 67Ga (just 68 min), allowing patients to be given higher tracer doses and to be discharged almost free of the radioactivity. Furthermore, the uptake phase is short, as is the whole-body image acquisition, allowing a short imaging procedure. Finally, PET/CT diagnostics produce high-spatial-resolution functional tomographic images that are then fused to low-dose anatomic CT images, exactly localizing all the pathologic findings (3).
Given those possible advantages of 68Ga-citrate PET/CT, the aim of this work was to preliminarily evaluate the sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of 68Ga-citrate PET/CT in a population of patients with suspected bone infections.
MATERIALS AND METHODS
Patient Population
This study was approved by the Ethical Committee of our hospital. We enrolled 31 patients from January 2008 to February 2009 (18 men and 13 women; mean age ± SD, 42 ± 18 y). The patients had entered the protocol to be evaluated for acute osteomyelitis (18 patients), chronic osteomyelitis (4 patients), or diskitis (9 patients). All patients who were referred for a 68Ga-citrate PET/CT scan were suspected of having a bone infection on the basis of clinical symptoms, risk factors, inflammatory serum marker levels, and the results of standard imaging (MRI in patients without bone implants, with or without radiography). Biopsy was performed after 68Ga-citrate PET/CT.
Among the 31 patients, 7 had a bone implant or prosthesis. Twenty patients underwent 68Ga-citrate PET/CT only before therapy, 9 patients underwent two 68Ga-citrate PET/CT scans (one before therapy and the other after antibiotic therapy with or without surgical curettage), and 2 patients underwent 68Ga-citrate PET/CT only after antibiotic therapy. A total of forty 68Ga-citrate PET/CT scans were obtained (Table 1).
68Ga-Citrate Synthesis
68Ga-citrate was synthesized according to the method described in a previous publication (4). Briefly, a 68Ge/68Ga generator was produced by Eckert & Ziegler Isotope Products GmbH, and 68Ga-citrate syntheses were performed on a commercial adapted module used for the routine labeling of 68Ga-DOTANOC (3).
68Ga-Citrate PET/CT
All patients underwent 68Ga-citrate PET/CT (whole-body or segmental) using a 3-dimensional scanner (Discovery STE; GE Healthcare). They were intravenously injected with a mean dose of 167 MBq of 68Ga-citrate, and the uptake time was 60 min.
Fasting was not required. PET images were acquired in 3-dimensional mode for 4 min per bed position and reconstructed using a fully 3-dimensional iterative algorithm (ViewPoint algorithm [GE Healthcare], 2 iterations and 20 subsets), and attenuation correction was based on low-dose CT.
The PET/CT images were reviewed by 2 experienced nuclear medicine physicians aware of the clinical data, and the diagnosis was reached by consensus. For each patient, data about the clinical situation were accessible at the moment of the 68Ga-citrate PET/CT scan, such as the site of the pain, the presence of a bone prosthesis or implant at the site of the pain, the inflammatory marker levels, and the results of other imaging procedures. The complete imaging flow chart is reported in Supplemental Table 1 (supplemental materials are available online only at http://jnm.snmjournals.org). The scan interpretation was visual. All areas presenting tracer uptake visibly higher than the background level at the site of the suspected bone infection were considered positive. Maximum standardized uptake value (SUVmax) (normalized to body weight) was calculated lesion by lesion, and mean standardized uptake value (SUVmean) was calculated for normal bone marrow.
Results Validation
The data were validated by comparing the PET/CT results with the results of biopsy, serum inflammatory markers (for the assessment of response to therapy), white blood cell scintigraphy, clinical follow-up, and conventional diagnostic imaging (MRI or CT in patients without a prosthesis or bone implant, or radiography). Clinical follow-up consisted of clinical evaluation of the patients approximately every 6 mo for at least 1 y.
A standard flow chart for all patients was not possible because of differences in the natural history of diskitis, acute osteomyelitis, and chronic osteomyelitis; the generally low accuracy of conventional imaging and biopsy; the inapplicability of MRI to patients with a bone implant or prosthesis; the pronounced artifacts on CT images related to bone implants; and the different therapy approaches. The final diagnosis was reached by agreement of different combinations of diagnostic procedures.
Data Analysis
Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated by comparing the PET results to biopsy (if diagnostic) or to the combination of follow-up data and conventional imaging results.
RESULTS
Normal Biodistribution of 68Ga-Citrate
The normal distribution is represented in Figure 1. Of interest is the relatively high vascular activity, which is not typical of 67Ga-citrate scintigraphy. 68Ga-citrate showed moderate hepatic uptake associated with mild bone marrow activity. The uptake was like that seen with 67Ga-citrate but less intense. No bowel activity was present.
Performance of 68Ga-Citrate PET/CT
All acquired images were diagnostic.
The validation procedures are reported in Supplemental Table 1. All patients underwent biopsy, but only 11 of 30 biopsy samples (37%) were diagnostic. Details on the true-positive, true-negative, false-positive, and false-negative scans are reported in Table 1 and Figures 2–4.
Overall, we found 4 false-positive scans, 23 true-positive scans, 13 true-negative scans, and no false-negative scans, resulting in a sensitivity of 100%, a specificity of 76%, a positive predictive value of 85%, a negative predictive value of 100%, and an overall accuracy of 90%.
We did not find significant tracer uptake in uninfected bone implants.
SUVmax Analysis
Positive 68Ga PET/CT scans presented a mean SUVmax of 4.4 ± 1.8. The SUVmax was 3.9 ± 1.8 (range, 1.7–8.0) for acute osteomyelitis, 5.5 ± 2.0 (range, 4.0–7.0) for chronic osteomyelitis, and 5.8 ± 2.0 (range, 3.7–8.6) for diskitis. Because of the small number of positive PET/CT scans performed for chronic osteomyelitis and diskitis (2 and 4, respectively), it was not possible to apply any statistical study, but the 3 groups of patients seemed to be equal because of the SUVmax overlap.
The normal bone marrow SUVmean ranged from 0.8 to 2.9. On average, the bone marrow SUVmean was 1.5. We found an increased diffuse uptake in the bone marrow of a pediatric patient (10 y old, 4.1), but this finding may represent a normal distribution in children.
DISCUSSION
The diagnosis of bone infection has long been an issue and has been approached with several imaging methods, but the optimal diagnostic procedure or a standard diagnostic flow chart has not yet been identified (5).
Biopsy of the infected area is an invasive procedure and not always diagnostic (50% sensitivity has been reported) (6–8). MRI is a sensitive but nonspecific technique and is contraindicated in patients with a prosthesis or bone implant (9). Morphologic imaging procedures are not specific and may present significant artifacts in patients with a prosthesis. Furthermore, these tests are not reliable for the diagnosis of response to antibiotic therapy (10,11). WBC scintigraphy is generally sensitive and specific for the nonaxial skeleton, but the procedure is long and complicated (12).
Overall, bone scanning, white blood cell scintigraphy, and MRI have a sensitivity and specificity of 82%–25%, 84%–80% (21%–60% for axial skeleton), and 84%–60%, respectively (9). According to our results, the performance of 68Ga-citrate PET/CT is not really superior to that of a conventional imaging diagnostic flow chart (we found a slightly higher sensitivity and a comparable specificity, but the population evaluated was still limited). Its added value basically relies on a simple and fast diagnostic procedure, the absence of contraindications to scanning (no false positivity in cases of bone implants), and low dosimetry due the short half-life.
The short half-life of 68Ga-citrate, although an advantage from a dosimetric point of view, could be considered a drawback at the same time because it does not allow the long uptake time typical of 67Ga-citrate scintigraphy. This difference is illustrated by the slightly different biodistribution of the 2 compounds in the whole-body acquisition (Fig. 1). Our final results show that a short uptake time is long enough to visualize a pathologic process although a longer time would have guaranteed a higher contrast due to reduction of the background (13). The relatively low SUVmax, in comparison to the background, that was found in most patients with bone infection witnesses this concept. Although we used visual criteria to decide on all positive findings (and therefore the tracer uptake was significantly higher than the background), most patients had an SUVmax between 2 and 4—a value that certainly does not clearly highlight the infected area at first glance on the maximum-intensity-projection image. Each scan was therefore carefully reviewed slice by slice.
We had false-positive results in patients with tumors. This event was predictable because 67Ga-citrate has long been used as a cellularity marker. It was not possible to explore causes of false positivity other than malignancies. The patient population, in fact, did not include recently operated patients or patients with recent bone fractures. Patients with bone implants showed significant artifacts on the CT images but no false-positive results in the corresponding PET series, thanks to a correction of the ViewPoint iterative algorithm.
It is interesting that no false-negative results were found and that the negative predictive value of 68Ga-citrate PET/CT was therefore quite high. This finding was confirmed by a previous preclinical publication (14).
The main limitation of this study concerned the gold standard used to validate the PET/CT results—a long follow-up—which is the only reliable approach due to the cited limitations of other diagnostic procedures.
The importance of functional images is not limited to the diagnosis of infection but extends also to surgical planning. The fusion of 68Ga-citrate PET images and CT images allows the surgeon to have an accurate and detailed base to better plan the operation and possibly improve patient outcome.
Many authors suggest that, besides 68Ga-citrate, the more standard 18F-FDG be used as an in vivo marker of bone infection. 18F-FDG is sensitive but has the great limitation of giving positive results in patients with a bone prosthesis, even if there is no infection or mobilization (15). In our population, many patients had different types of prostheses or bone implants but 68Ga-citrate was positive only in cases of infection. However, a direct comparison of the performance of the 2 tracers is important, and no more comments can be made without such a comparison.
CONCLUSION
68Ga-citrate PET/CT is a new diagnostic tool that can be considered in the flow chart of patients with bone infection. However, more experience is required to further validate these results.
- © 2010 by Society of Nuclear Medicine
REFERENCES
- Received for publication June 14, 2010.
- Accepted for publication August 30, 2010.